Swiftsure International Inc.
Holmes Biopharma, Inc.: Strong Sales Start for 2008

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

HOLMES BIOPHARMA  – Strong Sales Start for 2008

Scottsdale, Arizona – March 13, 2008 –  Holmes Biopharma, Inc. (Symbol
HHJA, security code AOKDRX) announces that its Omaha, Nebraska based
clinical research facility is experiencing a strong sales start for 2008.
The company has committed contracts of approximately US$4 million, and an
additional US$10 million in outstanding proposals.  Both figures indicate
that the company is on course to meet its sales objective of increasing
2007 revenue by 100%.

'Several follow-up projects from repeat customers show the strong following
we now have due to exceptional quality and delivery of services', stated
John Metcalfe, President HolmesBiopharma Inc.

About Holmes:
Holmes Biopharma Inc. is a contract research organization focused on
providing integrated and cost effective clinical development services that
help the pharmaceutical industry introduce new drug products rapidly from
laboratory to the market. It currently has clinics in Omaha, Nebraska,
Toronto, Canada and Kiev, Ukraine, Eastern Europe For more information
about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe, President and CEO, HolmesBiopharma Inc.

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:

www.holmesbiopharma.com
Tel: 1-800-778-4990 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
13.03.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------